Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Marco Falcone et al.|JAMA|2018Cited by 761
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old FoeSteven Y. C. Tong, Adrian Dunlop, Jocelyn Mora et al.|Clinical Infectious Diseases|2022Cited by 98
Outpatient parenteral antimicrobial therapy for patients with <i>Enterococcus faecalis</i> endocarditis using continuous infusion IV benzylpenicillin plus IV ceftriaxoneSimon Briggs, Simon C. Dalton, Eamon Duffy et al.|JAC-Antimicrobial Resistance|2024Cited by 3